Navigation Links
Dainippon Sumitomo Pharma and Intercept Pharmaceuticals Announce Agreement to Develop and Commercialize Obeticholic Acid (INT-747) for Chronic Liver Disease
Date:3/30/2011

OSAKA, Japan and NEW YORK, March 30, 2011 /PRNewswire/ -- Dainippon Sumitomo Pharma Co, Ltd. (DSP) and Intercept Pharmaceuticals, Inc. (Intercept) today announced that they have entered into an exclusive licensing agreement for the development and commercialization of Intercept's first-in-class FXR agonist obeticholic acid (OCA, also known as INT-747). DSP will advance OCA in Japan and China for the treatment of chronic liver diseases, with an initial focus on primary biliary cirrhosis (PBC) and nonalcoholic steatohepatitis (NASH). Intercept is currently preparing for the initiation of a Phase III PBC program in the US and Europe and, under the company's cooperative research and development agreement (CRADA) with the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), a large placebo-controlled trial of OCA in NASH patients recently started enrolling in the US.

Under the terms of the licensing agreement, Intercept will receive an initial payment from DSP of $15 million and will be eligible to receive approximately $300 million in additional milestone payments associated with the successful development and commercialization of OCA. Upon launch of OCA, Intercept will be entitled to receive tiered double-digit royalties from DSP based on sales in its territory. DSP has the exclusive option to add several other Asian countries to its territory, including Korea and Taiwan, and to pursue additional indications. DSP will be responsible for the costs of developing and commercializing OCA in its territory.

"OCA is an important strategic addition to our growing pipeline of hepatology drugs and reflects DSP's strong commitment to specialty therapeutic areas," said Masayo Tada, President and CEO of DSP. "There is a very high unmet medical need in the hepatology area in Asia and DSP's marketed products SUMIFERON®, a natural alpha interferon, and MIRIPLA®, a therapeutic agent for hepatocellular carcinoma, benefit many thousands of
'/>"/>

SOURCE Intercept Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Codexis Signs First Japanese Biocatalysis Collaboration With Dainippon Sumitomo Pharma
2. Dainippon Sumitomo Pharma America Announces FDA Acceptance of Lurasidone New Drug Application for Treatment of Schizophrenia
3. Dainippon Sumitomo Pharma Announces Lurasidone Phase III Data in Patients With Schizophrenia
4. Pharmasset Initiates Phase 2b ATOMIC Trial of PSI-7977 for Multiple HCV Genotypes
5. Isis Pharmaceuticals to Present at the 10th Annual Needham Healthcare Conference
6. Konica Minolta Sensing Announces CM-5 Spectrophotometer to Pharmaceutical Industry at Interphex 2011
7. Valeant Pharmaceuticals Proposes to Acquire Cephalon, Inc. for $73 Per Share in Cash
8. SCOLR Pharma, Inc. Reports 2010 Financial Results, Provides Updates on Advances in Nutritionals, OTC Drugs
9. ViroPharma Initiates Phase 2 Study of C1 Esterase Inhibitor [Human] for Treatment of Antibody-Mediated Rejection (AMR)
10. New Survey Emphasizes Value of Biopharmaceutical Company Engagement With Healthcare Providers
11. LodgeNet Healthcare Partners With American Society of Health-System Pharmacists to Improve Clinical Outcomes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... RMD ) today announced results for its quarter ... million, a 10 percent increase compared to the quarter ended ... currency basis). Net income was $91.2 million, an increase of ... Diluted earnings per share for the quarter were $0.64, an ...
(Date:1/22/2015)... Jan. 22, 2015  Bio-Techne Corporation (NASDAQ: TECH ... first member of the new Simple Plex platform through ... launch represents the re-branding of the previously acquired CyPlex ... platform is a transformative immunoassay technology which integrates an ...
(Date:1/22/2015)... DUBLIN , Jan. 22, 2015 Research and Markets ... of the "Infectious Disease Diagnostics Market by Product, ... report to their offering. , The ... CAGR of 7.9% to reach $18,156.2 million by 2019 ...
Breaking Medicine Technology:ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 2ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 3ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 4ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 5ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 6ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 7ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 8ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 9ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 10ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 11Bio-Techne Launches Simple Plex Platform 2Bio-Techne Launches Simple Plex Platform 3Global Infectious Disease Diagnostics (Instruments, Reagents, Services, Software) Market - Forecast to 2019 2Global Infectious Disease Diagnostics (Instruments, Reagents, Services, Software) Market - Forecast to 2019 3
... Calif., Dec. 14, 2010 Samplify Systems, Inc., ... for the ultrasound market, is pleased to announce ... imaging has won Electronic Design Magazine,s ... medical category.  Details of Samplify,s AutoFocus™ beamforming technology ...
... VIVUS, Inc. (Nasdaq: VVUS ) today announced ... secure regulatory approval for QNEXA® in the U.S., submitted a ... to address items in the FDA,s Complete Response Letter (CRL), ... the Endocrine and Metabolic Division of the FDA has granted ...
Cached Medicine Technology:Samplify's AutoFocus™ Beamforming Technology Awarded Electronic Design's 'Best of 2010' 2VIVUS Submits Briefing Document to FDA, Announces Follow-up Meeting to Discuss QNEXA® 2VIVUS Submits Briefing Document to FDA, Announces Follow-up Meeting to Discuss QNEXA® 3
(Date:1/22/2015)... Woodloch Pines, an all-inclusive family resort located ... the number one best large hotel for families in the ... their annual Travelers’ Choice Awards. , TripAdvisor represents the ... home to millions of unbiased and honest traveler reviews. The ...
(Date:1/22/2015)... The Incredible Bulk is a revolutionary method put together by ... up to 30lbs in less than 12 weeks without traditional ... prompting an investigative review. , “Our Incredible Bulk review ... that allows the body to pack on a massive amount ...
(Date:1/22/2015)... York (PRWEB) January 22, 2015 The federal ... in the U.S. District Court, Southern District of West Virginia ... Inc. in that proceeding’s first bellwether trial. In an Order ... a new trial after finding that C.R. Bard had not ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Autocarinsurancebest.com has released ... purchasing a commercial auto insurance policy . , Auto ... their vehicles. It is no longer necessary to call an ... are now available online on a single website: http://autocarinsurancebest.com/ ...
(Date:1/22/2015)... A study recently published in ... Medicine & Science in Sports & Exercise shows ... reduce gastrointestinal (GI) problems associated with physical strain ... the double-blind, placebo-controlled study took 10 grams of ...
Breaking Medicine News(10 mins):Health News:TripAdvisor Names Woodloch Pines Best Hotel for Families in America 2Health News:TripAdvisor Names Woodloch Pines Best Hotel for Families in America 3Health News:The Incredible Bulk: Review Examining Ben Pakulski’s Brand New Bulking Muscle Building Diet Program Released 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4Health News:Commercial Auto Insurance Provides Several Important Features! 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3
... with Life ... Insurance Awareness Month, PHILADELPHIA, Sept. 4, 2007 ... complex and confusing -- half don,t know how much to buy ... consumers learn,more about life insurance, CIGNA Group Insurance has created a ...
... tips to rid homes of common allergens, OMAHA, Neb., ... our time indoors getting bombarded by contaminants and,allergens, such as ... are built so air-tight that any air that gets in ... making your housekeeping,practices all the more important. Try to ...
... More Precisely Stage, Diagnose ... and Treat Lung Cancer, ... US-based organization devoted exclusively to,patient support and advocacy for those living ... investigators of the,International Association for the Study of Lung Cancer (IASLC) ...
... move more and eat smart, BOSTON, Sept. 4 ... report that again this year, obesity rates climbed in,31 ... Foundation(R) (AOMF),and YMCA of the USA,s YMCA Activate America(R) ... highlighting the,benefits of healthy, active living., AOM,s research-based ...
... Despite recommendations for annual preventive exams for adolescents, only 10 ... receive the recommended three shots needed for HPV vaccine. Ideally ... 1 percent of teens see their physicians that often. ... need all three shots before they are exposed to the ...
... OVATION Pharmaceuticals, Inc. announced the initiation of ... a unique 1,5 benzodiazapine with significant anticonvulsant properties, ... (LGS), one of the most severe forms of ... previous studies clobazam was shown to be well ...
Cached Medicine News:Health News:CIGNA Group Insurance Shows Consumers 'There's More to Life' Through a New Consumer Education Toolkit 2Health News:CIGNA Group Insurance Shows Consumers 'There's More to Life' Through a New Consumer Education Toolkit 3Health News:Clean to Ease Allergy and Asthma Symptoms 2Health News:LCA Hails International Investigators Studying Lung Cancer 2Health News:America On the Move and More Than 1,500 YMCAs Kick Off Steptember 2007 2Health News:America On the Move and More Than 1,500 YMCAs Kick Off Steptember 2007 3Health News:America On the Move and More Than 1,500 YMCAs Kick Off Steptember 2007 4Health News:Teens need to see their doctors more often 2Health News:Ovation further advances development pipeline with new phase III epilepsy study 2
... Experience the finest surgical-quality loupes available ... the standard for innovative optical design, ... support. Delivering optimum performance with maximum ... choice for medical professionals worldwide. All ...
... the finest surgical-quality loupes available ... standard for innovative optical design, combining ... optimum performance with maximum comfort, SheerVision ... medical professionals worldwide. Make both a ...
... loupes available at manufacturer-direct prices. ... optical design, combining superior quality withunmatched ... maximum comfort, SheerVision loupes are the ... Make both a professional and a ...
... loupes available at manufacturer-direct prices. ... optical design, combining superior quality withunmatched ... maximum comfort, SheerVision loupes are the ... Make both a professional and a ...
Medicine Products: